Morgan Stanley Has Lowered Expectations for Certara (NASDAQ:CERT) Stock Price

Certara (NASDAQ:CERT) had its target price reduced by stock analysts at Morgan Stanley from $16.00 to $12.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective suggests a potential upside of 32.23% from the company’s current price.

A number of other equities research analysts have also recently commented on the stock. Stephens decreased their target price on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, December 12th. BMO Capital Markets assumed coverage on Certara in a research report on Thursday, November 13th. They issued a “market perform” rating and a $9.00 price objective on the stock. Craig Hallum started coverage on Certara in a research note on Monday, September 29th. They issued a “buy” rating and a $16.00 price objective for the company. Wall Street Zen raised Certara from a “hold” rating to a “buy” rating in a research note on Monday, November 24th. Finally, Rothschild Redb raised Certara to a “strong-buy” rating in a report on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $12.91.

Certara Stock Performance

NASDAQ CERT traded up $0.22 on Thursday, hitting $9.08. 902,419 shares of the company traded hands, compared to its average volume of 1,824,872. The business’s 50 day moving average price is $10.17 and its 200-day moving average price is $10.81. Certara has a 52-week low of $8.02 and a 52-week high of $15.69. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of 129.64 and a beta of 1.46.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. Certara had a return on equity of 5.18% and a net margin of 2.62%.The firm had revenue of $104.62 million for the quarter, compared to the consensus estimate of $104.53 million. During the same quarter last year, the company earned $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. Equities analysts expect that Certara will post 0.28 earnings per share for the current year.

Institutional Trading of Certara

A number of large investors have recently added to or reduced their stakes in CERT. CIBC Bancorp USA Inc. bought a new position in shares of Certara during the 3rd quarter valued at approximately $2,844,000. Morningstar Investment Management LLC bought a new stake in Certara in the third quarter worth $1,598,000. Wasatch Advisors LP raised its stake in Certara by 28.6% during the third quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock valued at $212,608,000 after purchasing an additional 3,865,455 shares in the last quarter. Parkman Healthcare Partners LLC lifted its position in Certara by 10.4% during the third quarter. Parkman Healthcare Partners LLC now owns 551,850 shares of the company’s stock valued at $6,744,000 after purchasing an additional 51,850 shares during the last quarter. Finally, London Co. of Virginia grew its stake in shares of Certara by 5.6% in the 3rd quarter. London Co. of Virginia now owns 1,554,991 shares of the company’s stock worth $19,002,000 after buying an additional 82,283 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.